Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Dr. Freedland closes his discussion by highlighting remaining unmet needs in mCRPC treatment and providing some clinical pearls for community oncologists treating patients with the disease.

EP: 1.Case Presentation: A 67-Year-Old-Man with Metastatic Prostate Cancer

EP: 2.Available Systemic Therapy Options for Metastatic Castration-Resistant Prostate Cancer (mCRPC) After Docetaxel and AR-Targeted Therapy

EP: 3.Factors for Consideration When Selecting Treatments for Patients with mCRPC

EP: 4.The Impact of Using AR Pathway Inhibitors and Docetaxel in Early Treatment of Prostate Cancer

Now Viewing

EP: 5.Unmet Needs, Future Directions, and Clinical Pearls in mCRPC

Related Videos

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.

Related Content

Advertisement

January 23rd 2025

Health-related QOL is comparable among ARPI regimens for CSPC

Hannah Clarke

At 25 weeks, FACT-P total score remained comparable between the arms.

February 29th 2024

Dr. Murphy on increasing diversity in cancer clinical trials

Urology Times staff

In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.

January 13th 2025

FDA accepts NDA for 3-month leuprolide mesylate formulation for advanced prostate cancer

Hannah Clarke

The PDUFA target action date has been set for August 29, 2025.

January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic

Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.

January 7th 2025

Expanded indication sought for darolutamide in mHSPC in China

Hannah Clarke

The application is supported by data from the pivotal phase 3 ARANOTE trial.

January 1st 2025

2024 Urology Times pipeline report

Jason M. Broderick Hannah Clarke Brittany Lovely

Catch up on all the notable drug and device approvals in urology over the past year.